Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Pien Tze Huang Pharmaceutical is a China-based premium TCM manufacturer headquartered in Zhangzhou, Fujian. Founded in 1956 with a secret formula heritage tracing back to the Ming Dynasty, the company is protected under China's highest-level trade secret designation. With 2025 revenue of CNY 9.00 billion, Pien Tze Huang represents the ultimate luxury brand in Chinese medicine, employing approximately 3,000 staff at its specialized manufacturing facilities in Fujian province.

Core Business

Pien Tze Huang's core competency lies in its eponymous hepatoprotective product — a state-protected secret formula combining natural musk, bezoar, and other precious ingredients in a proprietary manufacturing process. Beyond its flagship liver care product, the company has successfully diversified into premium TCM cosmetics, functional health supplements, and operates an expanding network of 582 physical TCM clinics. Its recent breakthrough in securing Argentine natural bezoar import rights represents a strategic masterstroke in supply chain diversification.

Key Strengths

1. Irreplaceable competitive moat from China's highest-level state-protected secret formula. 2. Extraordinary brand value as both medicine and luxury gift — often called the "Moutai of Medicine." 3. Strategic breakthrough in international raw material sourcing (Argentine bezoar import license). 4. Successful brand extension into high-margin TCM cosmetics and supplements segments. 5. Growing healthcare ecosystem with 582 physical clinic locations integrating products and services.

Challenges & Outlook

2025 marked a historic inflection point: the first simultaneous revenue (-16.56%) and net profit (-27.49%) decline since its 2003 IPO. The root cause was a devastating raw material cost timing mismatch — settling 2024's peak-price bezoar inventory through 2025 production cycles. Core product inventory exploded 265.53%, and operating cash flow collapsed 94.14%. However, with bezoar prices normalized and import channels opened, 2026 should see significant margin recovery. VerityRank Score of 85/100 acknowledges the unparalleled brand moat while reflecting the current cyclical headwinds.